Hengrui insists on "scientific and technological innovation" as the company's primary strategy for development, and has formed an independent and complete innovation system with a clear division of labor and unified collaboration, which has laid a solid foundation for new drug research and development.Learn more
The company always adheres to the development concept of "talent is the first resource", continuously introduces high-level talents at home and abroad, gives full play to the leading role of high-end talents, makes every effort to build a talented height, and promotes the innovation and development of enterprises.Learn more
The company focuses on academic exchanges and market promotion, and has established a marketing network throughout the country, forming a professional, standardized and orderly perfect market system to provide patients with more professional and accurate services.Learn more
Recently, Hengrui Medicine received the "Clinical Trial Notification" for the company's pirlotinib tablets, SHR6390, and SHR-1316 injections approved by the State Drug Administration and approved the combination of pirlotinib maleate tablets A randomized, double-blind, parallel-controlled, totuzumab plus docetaxel versus placebo combined with trastuzumab plus docetaxel for early or locally advanced HER2-positive breast cancer before surgery ...
Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration and approved the company's Celecoxib capsules for sale. Celecoxib is a non-steroidal anti-inflammatory drug that selectively inhibits COX-2. It is mainly used to relieve the symptoms and signs of osteoarthritis, adult rheumatoid arthritis and ankylosing spondylitis, and to treat acute pain in adults. The original drug was approved by the US FDA in 1998 ...
Today (November 28), the National Medical Security Administration, the Ministry of Human Resources and Social Security announced the full version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue" in 2019. Tinib tablets and thiopefilgrastim injection were successfully negotiated and included in the national health insurance catalog
Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration and approved the company's esketamine hydrochloride injection for sale.